Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

AbCellera Biologics Inc. ABCL

Set alert

Price alert · ABCL

All alert types
11.12 USD -1.15 -9.37%

At close

11.24 +0.12 +1.08%

Pre-market · Nov 3, 8:00 AM ET

Bid
11.11 × 1
Ask
11.12 × 1
11.05 Day range 12.29
2.75 52-week range 15.02
YTD
+225.15%
1 year
+107.08%
Open
12.33
Prev close
12.27
Mkt cap
3.60B
Vol
3.04M
Avg vol
6.40M
EPS
-0.54
P/E
0.00
Div yield
0.00%
More statistics
Low
11.05
High
12.29
Forward P/E
-14.58
Beta
1.59
Short ratio
5.65
Inst. own
40.76%
Dividend
0.00
Ex-div date
Earnings
Nov 9, 2026
50-d avg
12.29
200-d avg
6.85
1y target
17.17

1D chart

Chart tools
Interval
1m5m15m30m

Signals (69)
NameTimeAgo
RSI: Oversold3:57 PM16 hours ago
MACD: Sell Signal3:55 PM16 hours ago
MACD: Buy Signal3:43 PM16 hours ago
RSI: Oversold3:35 PM16 hours ago
RSI: Oversold3:31 PM16 hours ago
SMA: Bearish3:30 PM16 hours ago
MACD: Sell Signal3:25 PM16 hours ago
MACD: Buy Signal3:18 PM16 hours ago
MACD: Sell Signal3:14 PM16 hours ago
SMA: Bullish3:05 PM17 hours ago
SMA: Bearish3:04 PM17 hours ago
SMA: Bullish3:03 PM17 hours ago
SMA: Bearish3:02 PM17 hours ago
MACD: Buy Signal2:52 PM17 hours ago
MACD: Sell Signal2:49 PM17 hours ago
MACD: Buy Signal2:45 PM17 hours ago
SMA: Bearish2:31 PM17 hours ago
SMA: Bullish2:28 PM17 hours ago
SMA: Bearish2:25 PM17 hours ago
SMA: Bearish2:25 PM17 hours ago

Newest 20 of 69.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 17.17 +54.4% upside
Target (low)
9.00
Target (mean)
17.17
Target (high)
30.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy10
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 13
  • 1 month ago 11
  • 2 months ago 9

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

ABCL analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.17762-0.20 – -0.16-0.19+6.5%6.25M-30.2%6
Next quarter-0.17215-0.20 – -0.1429-0.03-473.8%7.05M-84.3%6
Current year-0.67409-0.73 – -0.63-0.49-37.6%26.37M-64.9%8
Next year-0.76251-0.96 – -0.56-0.67409-13.1%28.24M+7.1%7

Upgrades and downgrades

The latest rating changes

ABCL analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2026UBSInitiated—Buy
Sep 29, 2026JP MorganInitiated—Overweight
Aug 11, 2026Truist SecuritiesMaintainedBuyBuy
Aug 6, 2026StifelMaintainedBuyBuy
Aug 6, 2026Cantor FitzgeraldMaintainedOverweightOverweight
Jul 7, 2026BenchmarkUpgradeHoldBuy
May 5, 2026Cantor FitzgeraldInitiated—Overweight
Apr 10, 2026Jones TradingInitiated—Buy
Nov 7, 2025Leerink PartnersDowngradeOutperformMarket Perform
Aug 8, 2025StifelMaintainedBuyBuy
Jul 14, 2025KeybancMaintainedOverweightOverweight
May 16, 2025Truist SecuritiesMaintainedBuyBuy
May 9, 2025StifelMaintainedBuyBuy
Apr 16, 2025KeybancMaintainedOverweightOverweight
Mar 3, 2025BenchmarkReiteratedHoldHold
Feb 28, 2025StifelMaintainedBuyBuy
Jan 8, 2025KeybancMaintainedOverweightOverweight
Nov 5, 2024BenchmarkReiterated—Hold
Nov 5, 2024StifelReiteratedBuyBuy
Aug 20, 2024BenchmarkDowngradeBuyHold
Jul 11, 2024KeybancMaintainedOverweightOverweight
May 8, 2024KeybancMaintainedOverweightOverweight
Feb 22, 2024BenchmarkUpgradeHoldBuy
Feb 21, 2024StifelMaintainedBuyBuy
Dec 5, 2023KeybancInitiated—Overweight
Aug 31, 2023BenchmarkMaintainedBuyBuy
Aug 4, 2023Goldman SachsMaintainedBuyBuy
May 5, 2023Credit SuisseMaintained—Outperform
Feb 28, 2023Cowen & Co.Initiated—Outperform
Feb 22, 2023BMO CapitalMaintained—Outperform